Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies
AW Roberts, DCS Huang - Clinical Pharmacology & …, 2017 - Wiley Online Library
The intracellular protein B‐cell‐lymphoma‐2 (BCL2) has been considered an attractive
target for cancer therapy since the discovery of its function as a major promoter of cell …
target for cancer therapy since the discovery of its function as a major promoter of cell …
[PDF][PDF] Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies
AW Roberts, DCS Huang - CLINICAL …, 2017 - minerva-access.unimelb.edu.au
The intracellular protein B-cell-lymphoma-2 (BCL2) has been considered an attractive target
for cancer therapy since the discovery of its function as a major promoter of cell survival (an …
for cancer therapy since the discovery of its function as a major promoter of cell survival (an …
Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies
AW Roberts, D Huang - Clinical pharmacology and …, 2017 - pubmed.ncbi.nlm.nih.gov
The intracellular protein B-cell-lymphoma-2 (BCL2) has been considered an attractive target
for cancer therapy since the discovery of its function as a major promoter of cell survival (an …
for cancer therapy since the discovery of its function as a major promoter of cell survival (an …
[HTML][HTML] Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies
AW Roberts, DCS Huang - Clinical Pharmacology and …, 2017 - ncbi.nlm.nih.gov
The intracellular protein B‐cell‐lymphoma‐2 (BCL2) has been considered an attractive
target for cancer therapy since the discovery of its function as a major promoter of cell …
target for cancer therapy since the discovery of its function as a major promoter of cell …
Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
AW Roberts, D Huang - Clinical Pharmacology and Therapeutics, 2016 - europepmc.org
The intracellular protein B‐cell‐lymphoma‐2 (BCL2) has been considered an attractive
target for cancer therapy since the discovery of its function as a major promoter of cell …
target for cancer therapy since the discovery of its function as a major promoter of cell …
[引用][C] Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies
AW Roberts, DCS Huang - Clinical Pharmacology & Therapeutics, 2016 - cir.nii.ac.jp
Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in
Chronic Lymphocytic Leukemia and Related B Cell Malignancies | CiNii Research CiNii 国立 …
Chronic Lymphocytic Leukemia and Related B Cell Malignancies | CiNii Research CiNii 国立 …
Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
AW Roberts, D Huang - Clinical Pharmacology and Therapeutics, 2016 - europepmc.org
The intracellular protein B‐cell‐lymphoma‐2 (BCL2) has been considered an attractive
target for cancer therapy since the discovery of its function as a major promoter of cell …
target for cancer therapy since the discovery of its function as a major promoter of cell …